AAPS PharmSci 360 2024: Predictive Models for Poorly Soluble Drugs

As a preview of what’s to come at this year’s AAPS PharmSci 360, being held Oct. 20–23, 2024 in Salt Lake City, Utah, Pharmaceutical Technology® sat down with Niloufar Salehi, advisor at Eli Lilly & Company, to discuss the problems associated with the formulation of poorly soluble drugs. Salehi also provided a look at how predictive models and other tools can be used to predict and improve solubility in both small-molecule and biologic drugs.

“There are several predictive tools that are used in order to determine poor solubility at [the] early stage of development,” says Salehi in the interview. “One of those is, for example, in silicon modeling that involves using computer simulations to provide insight on how [a] drug will behave in different media, and that can help scientists to identify the potential solubility issues before going any further. Also, another approach is high-throughput screening, which allows [a] researcher to quickly test the solubility of a large number of compounds, and that's enabled the scientists to identify whether there is any modification required for the further development.”

Click the above video to watch the full interview.

Salehi will be moderating the Symposium: Accelerated Development of Poorly Soluble Drugs Using Predictive Tool at AAPS PharmSci 360 on Tuesday, Oct. 22, 2024. Presentations include the following:

• Biorelevant Media and Relevance in Current Time
  Speaker: Sandra Klein, University of Greifswald
• Beyond Compendial In-Vivo Predictive Tools in Early Drug Product Development
  Speaker: Fady Ibrahim, Sanofi
• Role of Multi-Compartment Systems for Low-Solubility Weak Base Drug
  Speaker: Yasuhiro Tsume, University of Michigan
• Linking In-Vivo Predictive Dissolution Data with Pre-Clinical and Clinical Studies
  Speaker: Stephen D. Stamatis, Eli Lilly & Company.